Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis

Archives of Internal Medicine

Volumn 153, Issue 13, 1993, Pages 1541-1546

  Simonneau, Gerald ^a   Charbonnier, Bernard ^b   Decousus, Herve ^c   Planchon, Bernard ^d   Ninet, Jacques ^e   Sie, Pierre ^f   Silsiguen, Marc ^g   Combe, Sophie ^g  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c SERVICE DE NEUROLOGIE   (France)

^d HÔTEL DIEU   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f CHU PURPAN   (France)

^g Pharmuka Laboratories Neuilly Sur Seine ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; COMPARATIVE STUDY; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGE; RECURRENCE; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0027254958     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1993.00410130045005     Document Type: Article

References (30)

1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
2. Wilson JR, Langman J. Heparin therapy: a randomized prospective study. Am Heart J. 1979:97:155-158.
3. Hommes DW, Bura A, Mazzolai L, Buller HR, Tencate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med. 1992;116:279-284.
4. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 1986;315:1109-1114.
5. Hirsh J, Marder VJ, Salzman EW, et al. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. 2nd ed. Philadelphia, Pa: JB Lippincott Co; 1987:1266-1272.
6. Moser KM. Venous thromboembolism. Am Rev Respir Dis. 1990;141:235-249.
7. Girard P, Hauuy MP, Musset D, et al. Acute inferior vena cava thrombosis: early results of heparin therapy. Chest 1989;95:284-291.
8. Krupski WC, Bass A, Billay RB, et al. Propagation of deep venous thrombosis identified by duplex ultrasond. J Vasc Surg. 1990;12:467-475.
9. Salzman EW. Low molecular-weight heparin and other new antithrombotic drugs. N Engl J Med. 1992;326:1017-1019.
10. Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28:609-618.
11. Handeland GF, Abildgaard GF, Holm U, et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated heparin and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-112.
12. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 1982;59:1239-1245.
13. Holm HA, Ly B, Handeland GF, et al. Subcutaneous treatment of deep venous thrombosis: a comparison of unfractionated heparin and low molecular weight heparin. Haemostasis. 1986;16(suppl 2):30-37.
14. Albada J, Niewwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin): results of a double-blind randomized study. Circulation. 1989;80:935-940.
15. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost. 1990;64:506-510.
16. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicenter study. Thromb Haemost. 1991;65:251-256.
17. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard in proximal deep vein thrombosis. Lancet. 1992;339:441-445.
18. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med. 1992;326:975-982.
19. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
20. Samama M, Bernard P. Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988;75:128-133.
21. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988;60:407-410.
22. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-551.
23. Turpie AGG, Levine NN, Hirsh J, et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-933.
24. Marder VJ, Saulen RL, Atchartakam V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med. 1977;89:1018-1029.
25. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
26. Pollak EW, De Nardo S, Pollak M, et al. Detection of anticoagulant therapy failures in patients with venous thrombosis. Am J Surg. 1977;134:214-216.
27. Gallus A, Jackaman J, Tillet J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986; 2:1293-1296.
28. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared within 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
29. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res. 1982;25:475-485.
30. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. Drugs. 1990;40:498-530.